Completed NA INTERVENTIONAL 1-arm NCT00628368

Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer

Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of the EGFR in Response to Treatment With Neoadjuvant Chemoradiotherapy in Patients With Cancer of the Esophagus or Rectum

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Conditions Colorectal Cancer Esophageal Cancer

Interventions Gene expression analysis

Updated 7 times since 2017 Last updated: Feb 6, 2026 Started: Nov 30, 2005 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Colorectal Cancer and Esophageal Cancer and is currently completed. Institut du Cancer de Montpellier - Val d'Aurelle leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Completed NA
Sep 2024 — Feb 2026 [monthly]

Completed NA
Aug 2024 — Sep 2024 [monthly]

Completed NA

Status: Unknown → Completed
Jul 2024 — Aug 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut du Cancer de Montpellier - Val d'Aurelle

Data source: Institut du Cancer de Montpellier - Val d'Aurelle

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France